This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page
CommitmentHeritageInitiativesInnovationPortfolio

Menu

Close

Information on how to access prescribing information and adverse event reporting can be found at the bottom of this page.

A Proud Heritage of Cancer Research​​​​​​​

Pfizer has a proud heritage within oncology and we continue to work tirelessly in our pursuit to discover and develop innovative and accessible treatments for those living with cancer.1 

2000-2010

2003

  • Pfizer's efforts and investment in oncology begin to grow, increasing its oncology research and development projects by 400 percent over the next 5 years.1

2010

  • Pfizer’s treatment for adult patients with pancreatic neuroendocrine tumours (NETs) receives marketing authorisation in the EU, representing the first treatment for NETs in 25 years.2
2011-2020

2012

  • Pfizer's treatment for adult patients with advanced renal cell carcinoma receives marketing authorisation in the EU, providing a treatment option for patients that fail on first-line therapy.1
  • Conditional marketing authorisation is granted in the EU for Pfizer's tyrosine kinase inhibitor for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer.1

2013

  • Conditional marketing authorisation is granted in the EU for Pfizer's treatment for adult patients with chronic myelogenous leukaemia (CML) previously treated with one or more tyrosine kinase inhibitors.1

2016

  • Pfizer's cyclin-dependent kinase (CDK) 4/6 inhibitor receives marketing authorisation in the EU for the treatment of adult patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.1
  • Pfizer's tyrosine kinase inhibitor approved in the EU for the treatment of adult patients with ROS1-positive advanced NSCLC.1

2017

  • Pfizer's antibody-drug conjugate for the treatment for relapsed or refractory acute lymphoblastic leukaemia( ALL) is approved in the EU, offering a treatment option beyond chemotherapy.1

2018

  • Pfizer's treatment option for previously untreated, de novo, acute myeloid leukaemia (AML) receives marketing authorisation in the EU, marking the first therapy to target CD33.1
  • An extension to an existing indication for Pfizer's CML treatment is recommended in the EU, targeting CD33.1
  • Pfizer's oncology biosimilar receives marketing authorisation in the EU, gaining approval for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.1

2019

  • Pfizer's treatments for adult patients with epidermal growth factor receptor (EGFR) mutation-positive NSCLC and inherited BRCA-mutated locally advanced or metastatic breast cancer receives marketing authorisation in the EU.1
  • Conditional marketing authorisation is granted in the EU for Pfizer's third-generation ALK inhibitor – which was specifically developed to penetrate the blood-brain barrier – as a treatment for previously treated adult patients with ALK+ advanced NSCLC.1
  • Pfizer receives marketing authorisation in the EU for a biosimilar indicated for: Metastatic carcinoma of the colon or rectum; metastatic breast cancer; unresectable advanced, metastatic or recurrent NSCLC; advanced and/or metastatic renal cell cancer; and, persistent, recurrent or metastatic carcinoma of the cervix.1

2020

  • Pfizer's hedgehog pathway inhibitor for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) receives marketing authorisation in the EU.1
  • Pfizer's third oncology biosimilar is approved in the EU, for the treatment of adult patients with non-Hodgkin lymphoma and chronic lymphocytic leukaemia.1
2021 - Present

2022

  • Pfizer's ALK inhibitor receives marketing authorisation in the EU for first-line use in the treatment of adult patients with ALK+ advanced NSCLC.1
Related Content
Our Oncology Portfolio

Our portfolio of treatments stretches across multiple indications, including breast, genitourinary, blood and lung cancers.

Find out moreLoading
Innovation in Oncology

We believe nothing is more urgent, or more personal, than our goal to develop the next generation of potential cancer therapies.

Find out moreLoading
Commitment to Oncology

We're proud to partner with organisations that share our purpose to deliver the right treatment for each patient, at the right time.

Find out moreLoading
Initiatives in Oncology

In addition to manufacturing medicines, we're engaged in a number of initiatives that we hope will improve the lives of those impacted by cancer.

Find out moreLoading
Prescribing Information for Great Britain and Northern Ireland:
 
Besponsa®▼ (inotuzumab ozogamicin) Bosulif® (bosutinib)
Ibrance® (palbociclib) Inlyta® (axitinib)
Lorviqua®▼ (lorlatinib) Mylotarg®▼ (gemtuzumab ozogamicin)
Nivestim® (filgrastim) Retacrit® (epoetin zeta)
Ruxience®▼ (rituximab)  Sutent® (sunitinib malate)
Trazimera® (trastuzumab) Xalkori® (crizotinib)
Zirabev®▼ (bevacizumab)  


 

References:

1. Pfizer data on file.

2. Cision PR Newswire. SUTENT® Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET). December 2010. Available at: https://www.prnewswire.com/news-releases/sutent-receives-european-approval-for-a-new-indication-in-progressive-pancreatic-neuroendocrine-tumors-net-111182379.html. Last accessed September 2023. 

PP-UNP-GBR-6631. October 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​